These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35537891)

  • 1. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.
    Limonte CP; Hall YN; Trikudanathan S; Tuttle KR; Hirsch IB; de Boer IH; Zelnick LR
    J Diabetes Complications; 2022 Jun; 36(6):108204. PubMed ID: 35537891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
    Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
    Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry.
    García-Vega D; Cinza-Sanjurjo S; Eiras S; González-Juanatey JR
    Am J Med; 2024 Aug; 137(8):761-769.e1. PubMed ID: 38729592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Gao Y; Peterson E; Pagidipati N
    Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
    Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Chin K; Kimura M; Saito N; Kanaoka T; Aoyama T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Machimura H; Hishiki T; Umezawa S; Shimura H; Nakajima S; Yamamoto H; Sato K; Miyakawa M; Terauchi Y; Tamura K; Kanamori A
    Diabetes Res Clin Pract; 2022 Mar; 185():109231. PubMed ID: 35131376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.
    Lyu B; Sang Y; Selvin E; Chang AR; Alexander GC; Cohen CM; Coresh J; Shalev V; Chodick G; Karasik A; Carrero JJ; Fu EL; Xu Y; Grams ME; Shin JI
    Diabetes Care; 2022 Dec; 45(12):2926-2934. PubMed ID: 36282149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
    Sohn M; Nam S; Nauck MA; Lim S
    BMC Med; 2024 Jul; 22(1):273. PubMed ID: 38956548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chen WJ
    Diabetologia; 2022 Dec; 65(12):2032-2043. PubMed ID: 35945333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
    Kalra S; Bhattacharya S; Kapoor N
    J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Kobayashi K; Toyoda M; Hatori N; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Res; 2021; 2021():6573369. PubMed ID: 35028319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
    Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
    Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.